Palliative Osimertinib Rechallenge Achieving Rapid Improvement in Leptomeningeal Carcinomatosis After Prior Osimertinib-Induced ILD.

Akina Nigi, Keisuke Iwamoto, Hidetoshi Itani, Shigeto Kondou

Abstract read

In one paragraph

Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Palliative Osimertinib Rechallenge Achieving Rapid Improvement in Leptomeningeal Carcinomatosis After Prior Osimertinib-Induced ILD.Respirology case reports · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akina NigiDepartment of Respiratory Medicine Japanese Red Cross Ise Hospital Ise Mie Japan.ORCID https://orcid.org/0000-0001-9167-5836

Keisuke IwamotoDepartment of Respiratory Medicine Japanese Red Cross Ise Hospital Ise Mie Japan.

Hidetoshi ItaniDepartment of Respiratory Medicine Japanese Red Cross Ise Hospital Ise Mie Japan.

Shigeto KondouDepartment of Respiratory Medicine Japanese Red Cross Ise Hospital Ise Mie Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with EGFR-mutant lung cancer developed leptomeningeal carcinomatosis years after osimertinib-induced ILD. With no other treatment options, palliative osimertinib rechallenge led to rapid neurological improvement and radiological response, without ILD recurrence. This case highlights the potential of carefully monitored osimertinib rechallenge for symptomatic relief in exceptional cases.

Indexed as

EGFR mutationinterstitial lung diseaseleptomeningeal carcinomatosisosimertinibrechallenge

Identifiers

PMID41537168

DOI10.1002/rcr2.70467

PMCPMC12796502

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.